Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis

Robert J. Hoyer, Nelson Leung, Thomas Elmer Witzig, Martha Lacy

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Refractory pleural effusions present a challenging management problem and are associated with a poor prognosis in patients with primary systemic amyloidosis (AL). We report a series of four patients with AL who presented with bilateral pleural effusions that were refractory to diuretic therapy. After treatment with bevacizumab, an antivascular endothelial growth factor (VEGF) antibody, three of the four patients had improvement in their pleural effusions, peripheral edema, and functional status. Additional studies are needed to further define the role of bevacizumab in the management of this group of patients.

Original languageEnglish (US)
Pages (from-to)409-413
Number of pages5
JournalAmerican Journal of Hematology
Volume82
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

Pleural Effusion
Diuretics
Endothelial Growth Factors
Amyloidosis
Therapeutics
Vascular Endothelial Growth Factor A
Edema
Bevacizumab
Primary amyloidosis
Antibodies

Keywords

  • Amyloidosis
  • Bevacizumab
  • Pleural effusion
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. / Hoyer, Robert J.; Leung, Nelson; Witzig, Thomas Elmer; Lacy, Martha.

In: American Journal of Hematology, Vol. 82, No. 5, 05.2007, p. 409-413.

Research output: Contribution to journalArticle

@article{ecbea0e594d24f6d80b9ab62607737b1,
title = "Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis",
abstract = "Refractory pleural effusions present a challenging management problem and are associated with a poor prognosis in patients with primary systemic amyloidosis (AL). We report a series of four patients with AL who presented with bilateral pleural effusions that were refractory to diuretic therapy. After treatment with bevacizumab, an antivascular endothelial growth factor (VEGF) antibody, three of the four patients had improvement in their pleural effusions, peripheral edema, and functional status. Additional studies are needed to further define the role of bevacizumab in the management of this group of patients.",
keywords = "Amyloidosis, Bevacizumab, Pleural effusion, Vascular endothelial growth factor",
author = "Hoyer, {Robert J.} and Nelson Leung and Witzig, {Thomas Elmer} and Martha Lacy",
year = "2007",
month = "5",
doi = "10.1002/ajh.20858",
language = "English (US)",
volume = "82",
pages = "409--413",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis

AU - Hoyer, Robert J.

AU - Leung, Nelson

AU - Witzig, Thomas Elmer

AU - Lacy, Martha

PY - 2007/5

Y1 - 2007/5

N2 - Refractory pleural effusions present a challenging management problem and are associated with a poor prognosis in patients with primary systemic amyloidosis (AL). We report a series of four patients with AL who presented with bilateral pleural effusions that were refractory to diuretic therapy. After treatment with bevacizumab, an antivascular endothelial growth factor (VEGF) antibody, three of the four patients had improvement in their pleural effusions, peripheral edema, and functional status. Additional studies are needed to further define the role of bevacizumab in the management of this group of patients.

AB - Refractory pleural effusions present a challenging management problem and are associated with a poor prognosis in patients with primary systemic amyloidosis (AL). We report a series of four patients with AL who presented with bilateral pleural effusions that were refractory to diuretic therapy. After treatment with bevacizumab, an antivascular endothelial growth factor (VEGF) antibody, three of the four patients had improvement in their pleural effusions, peripheral edema, and functional status. Additional studies are needed to further define the role of bevacizumab in the management of this group of patients.

KW - Amyloidosis

KW - Bevacizumab

KW - Pleural effusion

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=34247530860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247530860&partnerID=8YFLogxK

U2 - 10.1002/ajh.20858

DO - 10.1002/ajh.20858

M3 - Article

C2 - 17326106

AN - SCOPUS:34247530860

VL - 82

SP - 409

EP - 413

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 5

ER -